- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07645300
LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial (LODESTAR)
8 juni 2026 uppdaterad av: VA Office of Research and Development
LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD (LODESTAR) Trial
The purpose of this research is to gather information on the safety and effectiveness of spironolactone and chlorthalidone for treatment of high blood pressure in patients with moderate to advanced CKD.
Both drugs have been approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure since 1960.
Studieöversikt
Status
Har inte rekryterat ännu
Detaljerad beskrivning
Highly prevalent among patients with chronic kidney disease (CKD) , poor blood pressure (BP) control is a modifiable risk factor for both kidney failure progression and cardiovascular (CV) disease.
Although the mineralocorticoid receptor antagonist (MRA) spironolactone (SPL) is recommended to treat resistant hypertension in patients with CKD, 34% discontinue SPL within 12 weeks, mostly due to hyperkalemia.
The potassium (K) binding agent patiromer reduced the discontinuation rate to 14%, but the added expense and potential drug interactions are of concern.
SPL, a steroidal MRA, reduces albuminuria and rates of decline in eGFR.
In type 2 diabetes and CKD, the non-steroidal MRA finerenone reduces kidney failure and CV outcomes but is not indicated for the treatment of hypertension.
Due to concern of hyperkalemia, SPL is barely prescribed in these patients.
In 2021, the investigators reported that chlorthalidone (CTD) in people with advanced CKD was effective in lowering BP and albuminuria by 50%.
However, reversible changes in kidney function and hypokalemia were common.
The investigators believe that a very low dose combination strategy of CTD + SPL will be effective in lowering BP, maintaining K, and providing target organ protection.
However, the optimal dose to maintain K and lower BP remains unclear.
To test this hypothesis, the investigators propose a pilot proof-of-concept study (phase 2A) followed by a larger phase 2B study.
Proof of Concept, phase 2A: To test the hypothesis that low or very low dose CTD combined with SPL will improve BP, the investigators will perform a pilot, single-center, placebo-controlled, double-blind, randomized trial among patients with CKD and poorly controlled hypertension.
After a two-week, patient-blind, placebo run-in, the investigators will randomize 50 hypertensive people to one of 4 groups in equal numbers: placebo; CTD very low dose; SPL very low dose QD; or a combination of CTD very low dose + SPL very low dose for 6 weeks.
At 6 weeks, doses will be doubled for a further 6 weeks.
The primary endpoint will be assessed by change from baseline to 6 weeks and 12 weeks in systolic AOBP and serum K for the combination group compared to placebo.
If CTD + SPL is more effective than placebo, the investigators will perform the phase 2B trial.
In this trial, the investigators will test the hypothesis that among patients with moderate to advanced CKD and poorly controlled hypertension, compared to add-on SPL or add-on CTD, treatment over 12 weeks with add-on combination of spironolactone (SPL) and chlorthalidone (CTD) will more effectively lower unattended systolic automated office blood pressure (uAOBP).
Furthermore, combination therapy will reduce albuminuria more than either drug alone providing evidence for target organ protection.
CTD will produce these effects by further reducing extracellular fluid volume in combination with SPL.
Studietyp
Interventionell
Inskrivning (Beräknad)
160
Fas
- Fas 2
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Rajiv Agarwal, MD MBBS
- Telefonnummer: (317) 988-2241
- E-post: rajiv.agarwal@va.gov
Studieorter
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202-2884
- Richard L. Roudebush VA Medical Center, Indianapolis, IN
-
Huvudutredare:
- Rajiv Agarwal, MD MBBS
-
Kontakt:
- Rajiv Agarwal, MD MBBS
- Telefonnummer: 317-988-2241
- E-post: rajiv.agarwal@va.gov
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Study is limited to US Veterans
- GFR estimated by race-independent CKD-EPI formula < 45 ml/min/1.73m2 but 15 mL/min/1.73m2
Hypertension
- The investigators will use clinic AOBP of at least 135/85 to define hypertension
Treatment with antihypertensive drugs
- This would require the use of at least one antihypertensive drug
- One of the drugs should be either an ACE inhibitor or ARB or a beta-blocker at the time of randomization
- Serum K 3.5 to 5.2 mEq/L at the time of randomization
Exclusion Criteria:
- Clinic AOBP of >=160/100 mmHg
Use of:
- SPL
- eplerenone
- amiloride
- triamterene
- finerenone
- thiazide
- thiazide-like drugs (CTD, HCTZ, metolazone, indapamide) or the use of K binders or fludrocortisone in the previous 4 weeks
- K supplementation would be allowed
- Myocardial infarction, heart failure hospitalization, or stroke 8 weeks prior to randomization
- If the patient is only on an alpha blocker, as the sole antihypertensive drug, they will be excluded
- Pregnant or breastfeeding women or women who are planning to become pregnant or those not using a reliable form of contraception
- Known hypersensitivity or a prior documented adverse reaction to CTD or SPL
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: placebo
phase 2A
|
very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks
very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks
very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks
|
|
Experimentell: Chlorthalidone
phase 2A Chlorthalidone(CTD) very low dose (VLD) x 6 weeks
|
very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks
|
|
Experimentell: Spironolactone
phase 2A Spironolactone(SPL) very low dose (VLD) x 6 weeks
|
very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks
|
|
Experimentell: CTD + SPL
phase 2A Chlorthalidone(CTD) VLD + Spironolactone(SPL) VLD x 6 weeks
|
very low dose (VLD) x 6 weeks then low dose (LD) x 6 weeks
|
|
Aktiv komparator: 2B CTD
phase 2B Chlorthalidone(CTD) low dose (LD) x 12 weeks
|
compare combination LD with SPL LD at 12 weeks
|
|
Aktiv komparator: 2B SPL
phase 2B Spironolactone(SPL) low dose (LD) x 12 weeks
|
compare combination LD with SPL LD at 12 weeks
|
|
Experimentell: 2B VLD CTD + VLD SPL
phase 2B Chlorthalidone(CTD) VLD + Spironolactone(SPL) VLD x 12 weeks
|
compare combination LD with SPL LD at 12 weeks
|
|
Experimentell: 2B LD CTD + LD SPL
phase 2B Chlorthalidone(CTD) LD + Spironolactone(SPL) LD x 12 weeks
|
compare combination LD with SPL LD at 12 weeks
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Unattended systolic automated office blood pressure in phase 2A
Tidsram: 12 weeks
|
phase 2A: the primary endpoint will be assessed by change from baseline to 6 weeks and 12 weeks in systolic AOBP for the combination group compared to placebo.
|
12 weeks
|
|
Serum K phase 2A
Tidsram: 12 weeks
|
phase 2A: the primary endpoint will be assessed by change from baseline to 12 weeks in serum K for the combination group compared to placebo.
|
12 weeks
|
|
Unattended systolic automated office blood pressure in phase 2B
Tidsram: 12 weeks
|
phase 2B: the primary endpoint will be assessed by change from baseline to 12 weeks in systolic AOBP for the combination LD group compared to SPL.
|
12 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Mediation of BP lowering by volume markers
Tidsram: 12 weeks
|
The investigators will evaluate changes from baseline in the following markers: B-type natriuretic peptide (BNP), seated plasma renin activity and plasma aldosterone, and 24h urinary aldosterone.
The investigators will use a mediation model to ascertain the mechanism of BP lowering whether it is via reduction of volume or blockade of the renin-angiotensin system.
Each of the 4 mediation variables will be analyzed individually and then in aggregate as prespecified in the statistical analysis plan.
|
12 weeks
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Utredare
- Huvudutredare: Rajiv Agarwal, MD MBBS, Richard L. Roudebush VA Medical Center, Indianapolis, IN
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
1 oktober 2026
Primärt slutförande (Beräknad)
31 mars 2032
Avslutad studie (Beräknad)
30 juni 2032
Studieregistreringsdatum
Först inskickad
8 juni 2026
Först inskickad som uppfyllde QC-kriterierna
8 juni 2026
Första postat (Faktisk)
12 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
12 juni 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
8 juni 2026
Senast verifierad
1 juni 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Patologiska processer
- Manliga urogenitala sjukdomar
- Njursjukdomar
- Urologiska sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Kronisk sjukdom
- Sjukdomsegenskaper
- Njurinsufficiens
- Patologiska tillstånd, tecken och symtom
- Hypertoni
- Njurinsufficiens, kronisk
- Organiska kemikalier
- Polycykliska föreningar
- Graviditet
- Steroider
- Fusion-ringföreningar
- Laktoner
- Gravid
- Spironolakton
Andra studie-ID-nummer
- NEPH-011-25F
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Ja
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
produkt tillverkad i och exporterad från U.S.A.
Ja
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .